United States: This week, the Advisory Committee on Immunization Practices (ACIP) proposed new vaccine guidelines to better protect Americans from RSV, meningitis, and the mosquito-borne chikungunya virus. The recommendations now await formal adoption by the CDC Director, following standard approval procedures, as reported by HealthDay.
Leadership in Transition May Impact Timing
Although the CDC typically finalizes these recommendations promptly, a shift in leadership may slow the process. President Donald Trump has nominated Susan Monarez as the next CDC Director. However, she must step aside from decision-making roles until confirmed by the U.S. Senate.
Until then, Health Secretary Robert F. Kennedy Jr.—who has long expressed skepticism toward vaccines—holds authority over such decisions, adding a layer of uncertainty to the process.
Who the New Vaccines Target
1. RSV Vaccine for At-Risk Adults (Ages 50–59)
Adults within this age group who have underlying conditions like heart disease, diabetes, or COPD are now recommended to receive the RSV vaccine.
ACIP voted to expand recommendation for toxic RSV shots to those 50 and over. This is shocking how it's still going on under this admin, but ultimately Makary and acting CDC director would have to sign off https://t.co/GOJ1RGgeW2
— Daniel Horowitz (@RMConservative) April 17, 2025
2. New 5-Strain Meningitis Vaccine
The FDA-approved vaccine by GSK protects against five types of meningococcal bacteria, including the strain responsible for campus outbreaks roughly a decade ago. It offers enhanced protection for adolescents and young adults.
3. Chikungunya Vaccine for Travelers 12+
A second chikungunya vaccine has been recommended for people aged 12 and older traveling to areas with ongoing transmission. Though rare in the U.S., the disease affects approximately 400 travelers annually, as reported by HealthDay.
FDA Issues Safety Alert for Older Adults
Health authorities at the FDA issued a safety warning regarding the live-virus chikungunya vaccine for adults above 65 years because of suspected heart and neurological issues in six vaccine recipients. Healthcare providers need to be consulted by patients in this age group especially when they have prior health problems. Current investigations continue to evaluate the situations.
